Uromune

Uromune
Vaccine description
TargetBacteria (E. coli, K. pneumoniae, E. faecalis, P. vulgaris)
Vaccine typeInactivated
Clinical data
Trade namesUromune
Other namesMV-140; MV140
Routes of
administration		Sublingual spray
ATC code
  • None

Uromune, also known by its developmental code name MV-140, is a polyvalent bacterial vaccine which is used and is being developed for prevention of recurrent urinary tract infections (UTIs).[1][2][3] In clinical studies, it has been found to reduce total number of UTIs by about 70%, to increase UTI-free rates from around 25% to 57%, and to increase time to next UTI from about 1.6 months to 9.0 months.[2][4][5][6] It has also been found to reduce subjective UTI symptoms, reduce antibiotic use, and improve quality of life.[2][4][5][6] The effectiveness of the vaccine appears to decrease with time, which might warrant readministration.[2][5][6][7] Uromune is used as a sublingual spray once daily for 3 months.[2][3][5]

Side effects of Uromune are considered infrequent, minor, and usually not treatment-related.[2] Uromune is an inactivated combination of four major bacteria known to cause recurrent UTIs, including Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris.[2] It is thought to work by increasing adaptive immunity against UTI-causing bacteria.[2][8] It might also work by increasing trained immunity against these pathogens.[2][8]

Uromune first became available for clinical use in 2010[2] and was first described in the literature by 2012.[9] It was developed and marketed in Spain by Inmunotek S.L.[1][10][9] Uromune has also been approved in Mexico and the Dominican Republic and is currently pending approval in Canada.[2][11][1] The vaccine is under development for use and is available via special-access programs in numerous other countries, including in many European countries, Australia, New Zealand, and Chile, among others.[1][2][11] Development and approval in the United States is in progress but is expected to take longer than in other countries.[6][11] Uromune is also under investigation for other uses besides prevention of uncomplicated recurrent UTIs in adults.[2] In addition, readministration of the vaccine following potential waning effectiveness is being studied.[2]

  1. ^ a b c d "MV 140". Adis Insight. Springer Nature Switzerland AG. Retrieved 15 February 2024.
  2. ^ a b c d e f g h i j k l m n Nickel JC, Doiron RC (February 2023). "An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women". Pathogens. 12 (3): 359. doi:10.3390/pathogens12030359. PMC 10052183. PMID 36986281.
  3. ^ a b Nickel JC, Saz-Leal P, Doiron RC (August 2020). "Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future". Can Urol Assoc J. 14 (8): 281–287. doi:10.5489/cuaj.6690. PMC 7402698. PMID 33626320.
  4. ^ a b Cite error: The named reference pmid38319200 was invoked but never defined (see the help page).
  5. ^ a b c d Cite error: The named reference pmid31806578 was invoked but never defined (see the help page).
  6. ^ a b c d Cite error: The named reference UrologyTimes2021 was invoked but never defined (see the help page).
  7. ^ Cite error: The named reference pmid36472057 was invoked but never defined (see the help page).
  8. ^ a b Cite error: The named reference pmid27966556 was invoked but never defined (see the help page).
  9. ^ a b Cite error: The named reference pmid22806485 was invoked but never defined (see the help page).
  10. ^ Cite error: The named reference pmid36861882 was invoked but never defined (see the help page).
  11. ^ a b c Cite error: The named reference PharmacyTimes2023 was invoked but never defined (see the help page).